About 1.7 billion people have been infected with Mycobacterium tuberculosis, the bacterial strain that causes tuberculosis. Unlike other treatment methods, scientists have developed a generic medication that may be beneficial to the immune system. These findings, according to InImmunity, may be beneficial for developing a more effective vaccine.
In some granulomas, immune activity stimulates bacterial clearance, but in others, bacteria thrive and grow. These are important traits in each individual.
Using one-cell profiling technique to recapitulate human TB, Shalek and his colleagues arranged for a monkey model to track and quantify bacterial load and killing in individual granulomas.
With TB, the immune response is quite good but not great, and until recently, the field has tackled this problem with very rudimentary tools. This collaboration is bringing the very best tools and the very best minds to bear on a really severe, very important problem that most of the world ignores, according to cosenior author Sarah Fortune, MD, chair of the Harvard Chan Department of Immunology and Infectious Diseases and an associate member of the Ragon Institute.
bacterial clearance in granulomas enriched with certain cellsspecifically mast, endothelial, fibroblast, and plasma cells has been identified. Granulomas that supported bacterial clearance are characterized by other types of cells, including type 1-type 17, stem-like, and cytotoxic T cells.
Shalek claims that our findings highlight fresh goals as well as specific cell subsetsto guide next-generation vaccines. We may also begin to examine how we might directly manipulate entire granulomas by modulating intercellular signaling to combat the bug more effectively.
Fortune argues that until the COVID-19 epidemic, TB was the leading cause of death from infectious disease across the globe. TB is the only way that we will be able to control COVID-19, which has entaild many of the characteristics that have made controlling COVID-19 difficult, particularly its airborne transmission, its infection in many people, and its ability to transmit before people are diagnosed. TB is not an effective vaccine, although currently, a number of infections are caused by bacteria, and TB are
The Bill and Melinda Gates Foundation, the Searle Scholars Program, the Beckman Young Investigator Program, the Sloan Fellowship in Chemistry, the National Institutes of Health, the American Lung Association, the National Science Foundation, the Fannie and John Hertz Foundation Fellowship, and the Wellcome Trust Fellowship have all given their support.